tetano
Editor, Senior Moderator
Biosens Bioelectron
. 2021 Mar 3;181:113134.
doi: 10.1016/j.bios.2021.113134. Online ahead of print.
Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing
Zehui Zhang[SUP] 1 [/SUP], Xiaoqin Wang[SUP] 2 [/SUP], Xiaojun Wei[SUP] 3 [/SUP], Sophia W Zheng[SUP] 1 [/SUP], Brian J Lenhart[SUP] 2 [/SUP], Peisheng Xu[SUP] 4 [/SUP], Jie Li[SUP] 5 [/SUP], Jing Pan[SUP] 6 [/SUP], Helmut Albrecht[SUP] 7 [/SUP], Chang Liu[SUP] 8 [/SUP]
Affiliations
Abstract
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread into a global pandemic. Early and accurate diagnosis and quarantine remain the most effective mitigation strategy. Although reverse transcriptase polymerase chain reaction (RT-qPCR) is the gold standard for COVID-19 diagnosis, recent studies suggest that nucleic acids were undetectable in a significant number of cases with clinical features of COVID-19. Serologic assays that detect human antibodies to SARS-CoV-2 serve as a complementary method to diagnose these cases, as well as to identify asymptomatic cases and qualified convalescent serum donors. However, commercially available enzyme-linked immunosorbent assays (ELISA) are laborious and non-quantitative, while point-of-care assays suffer from low detection accuracy. To provide a serologic assay with high performance and portability for potential point-of-care applications, we developed DNA-assisted nanopore sensing for quantification of SARS-CoV-2 related antibodies in human serum. Different DNA structures were used as detection reporters for multiplex quantification of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the nucleocapsid protein of SARS-CoV-2 in serum specimens from patients with conformed or suspected infection. Comparing to a clinically used point-of-care assay and an ELISA assay, our technology can reliably quantify SARS-CoV-2 antibodies with higher accuracy, large dynamic range, and potential for assay automation.
Keywords: Antibody; COVID-19; In vitro diagnostics; Nanopore; SARS-CoV-2.
. 2021 Mar 3;181:113134.
doi: 10.1016/j.bios.2021.113134. Online ahead of print.
Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing
Zehui Zhang[SUP] 1 [/SUP], Xiaoqin Wang[SUP] 2 [/SUP], Xiaojun Wei[SUP] 3 [/SUP], Sophia W Zheng[SUP] 1 [/SUP], Brian J Lenhart[SUP] 2 [/SUP], Peisheng Xu[SUP] 4 [/SUP], Jie Li[SUP] 5 [/SUP], Jing Pan[SUP] 6 [/SUP], Helmut Albrecht[SUP] 7 [/SUP], Chang Liu[SUP] 8 [/SUP]
Affiliations
- PMID: 33761415
- DOI: 10.1016/j.bios.2021.113134
Abstract
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread into a global pandemic. Early and accurate diagnosis and quarantine remain the most effective mitigation strategy. Although reverse transcriptase polymerase chain reaction (RT-qPCR) is the gold standard for COVID-19 diagnosis, recent studies suggest that nucleic acids were undetectable in a significant number of cases with clinical features of COVID-19. Serologic assays that detect human antibodies to SARS-CoV-2 serve as a complementary method to diagnose these cases, as well as to identify asymptomatic cases and qualified convalescent serum donors. However, commercially available enzyme-linked immunosorbent assays (ELISA) are laborious and non-quantitative, while point-of-care assays suffer from low detection accuracy. To provide a serologic assay with high performance and portability for potential point-of-care applications, we developed DNA-assisted nanopore sensing for quantification of SARS-CoV-2 related antibodies in human serum. Different DNA structures were used as detection reporters for multiplex quantification of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against the nucleocapsid protein of SARS-CoV-2 in serum specimens from patients with conformed or suspected infection. Comparing to a clinically used point-of-care assay and an ELISA assay, our technology can reliably quantify SARS-CoV-2 antibodies with higher accuracy, large dynamic range, and potential for assay automation.
Keywords: Antibody; COVID-19; In vitro diagnostics; Nanopore; SARS-CoV-2.